Clinical trial NCT00998192: A Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Squamous Cell Carcinoma of the Lung
Official title: A Phase 2 Study of Intravenous Administration of REOLYSIN® (Reovirus Type 3 Dearing) in Combination With Paclitaxel and Carboplatin in Patients With Squamous Cell Carcinoma of the Lung
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Metastatic or Recurrent Squamous Cell Carcinoma of the Lung
Keywords: carcinoma
squamous cell
lung
REOLYSIN
chemotherapy
carboplatin
paclitaxel
Carcinoma, Squamous Cell of the Lung
Lead sponsor: Oncolytics Biotech
Sponsor class: INDUSTRY
Collaborators: name: University of Texas
First posted: 2009-10-20
Enrollment: 32
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this Phase 2 study is to investigate whether intravenous administration of REOLYSIN therapeutic reovirus in combination with paclitaxel and carboplatin is effective and safe in the treatment of squamous cell carinoma of the lung.

Detailed description: Lung cancer remains the most common cancer and cause of cancer-related mortality in the United States. In 2008, there was an estimated 215,000 new cases of lung cancer diagnosed and roughly 162,000 deaths from lung cancer (NCI 2009). The majority (85%) of patients with a diagnosis of lung cancer will have non-small cell lung cancer (NSCLC).

The combination of paclitaxel and carboplatin has become the most commonly prescribed chemotherapy regimen for the treatment of advanced NSCLC in the United States. Laboratory studies of combinations of REOLYSIN with a variety of chemotherapeutic agents has shown that the combination of REOLYSIN and paclitaxel was invariably synergistic, even in cells with drug resistance or limited sensitivity to the reovirus. Moreover, reovirus activity was dramatically increased in the presence of the taxane.

The Phase 2 study is designed to characterize the efficacy and safety of REOLYSIN given intravenously in combination with paclitaxel and carboplatin every 3 weeks in patients with squamous cell carinoma of the lung.

Response is a primary endpoint of this trial.

The safety of the treatment combination will be assessed by the evaluation of the type, frequency and severity of adverse events, changes in clinical laboratory tests, immunogenicity and physical examination.

Patients may continue to receive chemotherapy combined with REOLYSIN for up to 8 cycles and may continue indefinitely on REOLYSIN monotherapy under this protocol, provided they have not experienced either progressive disease or unacceptable drug-related toxicity that does not respond to either supportive care or dose reduction.

Eligibility criteria: Inclusion Criteria:

* have histologically or cytologically confirmed metastatic stage IIIB (pleural effusion; IVA on revised IASLC staging) or stage IV, or recurrent squamous cell carcinoma of the lung.
* have measurable disease.
* be chemotherapy naïve for their metastatic or recurrent SCCLC, with some exceptions.
* have NO continuing acute toxic effects of any prior radiotherapy, chemotherapy, or surgical procedures.
* have an ECOG Performance Score of ≤ 2.
* have a life expectancy of at least 3 months.
* absolute neutrophil count (ANC) ≥ 1.5 x 10\^9; Platelets ≥ 100 x10\^9 (without platelet transfusion);Hemoglobin ≥ 9.0 g/dL (with or without RBC transfusion); Serum creatinine ≤ 1.5 x upper limit of normal (ULN); Bilirubin ≤ 1.5 x ULN; AST/ALT ≤ 2.5 x ULN.
* negative pregnancy test for females with childbearing potential.

Exclusion Criteria:

* receive concurrent therapy with any other investigational anticancer agent while on study.
* have a known past or current history of brain metastasis(es).
* be on immunosuppressive therapy or have known HIV infection or active hepatitis B or C.
* be a pregnant or breast-feeding woman.
* have clinically significant cardiac disease.
* have dementia or altered mental status that would prohibit informed consent.
* have any other acute, or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration or may interfere with the interpretation of study results and, in the judgment of the Principal Investigator, would make the patient inappropriate for this study.

Primary outcomes:
measure: Objective response rate (complete response (CR) + partial response (PR)) of the treatment regimen in the study population
timeFrame: 6 months
Secondary outcomes:
measure: Evaluate the safety and tolerability of the treatment regimen in the study population as measured by adverse events associated with the study treatment, and defined by established criteria.
timeFrame: Within 30 days of last dose of REOLYSIN
measure: To assess progression-free survival (PFS) for the treatment regimen in the study population.
timeFrame: 9-12 months
measure: Determine the proportion of patients receiving the treatment who are alive and free of disease progression at 6 months.
timeFrame: 6 months
measure: To determine overall survival with the treatment regimen in the study population
timeFrame: 9-12 months
Other outcomes:
Locations:
city: Los Angeles
country: United States
facility: Cedars-Sinai Medical Center
state: California
city: Ocala
country: United States
facility: Ocala Oncology Center
state: Florida
city: Niles
country: United States
facility: Illinois Cancer Specialists
state: Illinois
city: Indianapolis
country: United States
facility: Investigative Clinical Research of Indiana, LLC
state: Indiana
city: Armonk
country: United States
facility: Advanced Oncology Associates
state: New York
city: Middletown
country: United States
facility: Signal Point Clinical Research Center, LLC
state: Ohio
city: Kingston
country: United States
facility: Medical Oncology Associates of Wyoming Valley
state: Pennsylvania
city: Arlington
country: United States
facility: Texas Oncology - Arlington South
state: Texas
city: Bedford
country: United States
facility: Texas Oncology - Bedford
state: Texas
city: Denton
country: United States
facility: Texas Oncology - Denton South
state: Texas
city: Fort Worth
country: United States
facility: Texas Oncology - Fort Worth
state: Texas
city: Garland
country: United States
facility: Texas Oncology - Garland
state: Texas
city: Lewisville
country: United States
facility: Texas Oncology - Lewisville
state: Texas
city: San Antonio
country: United States
facility: Cancer Therapy & Research Center at UTHSCSA
state: Texas
city: San Antonio
country: United States
facility: Cancer Care Centers of South Texas
state: Texas
city: Tyler
country: United States
facility: Texas Oncology - Tyler
state: Texas
city: Lynchburg
country: United States
facility: Lynchburg Hematology Oncology Clinic
state: Virginia
Study officials:
affiliation: Cedars-Sinai Medical Center
name: Alain Mita, MD
role: PRINCIPAL_INVESTIGATOR
References: